Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients

Chemotherapy ◽  
2002 ◽  
Vol 48 (5) ◽  
pp. 252-258 ◽  
Author(s):  
Mehmet Akif Öztürk ◽  
İbrahim Barışta ◽  
M. Kadri Altundağ ◽  
Alev Türker ◽  
Şuayib Yalçın ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Single Center ◽  
Non Hodgkin’S Lymphoma ◽  
Single Center Study ◽  
Non Hodgkin's Lymphoma ◽  
Center Study

scholarly journals Primary breast non-Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

2009 ◽  
Vol 84 (3) ◽  
pp. 133-139 ◽  
Author(s):  
Patricia Validire ◽  
Mathieu Capovilla ◽  
Bernard Asselain ◽  
Youlia Kirova ◽  
Rémi Goudefroye ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Natural History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Single Center ◽  
Non Hodgkin’S Lymphoma ◽  
Single Center Study ◽  
Non Hodgkin's Lymphoma ◽  
Center Study

Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors

2006 ◽  
Vol 47 (7) ◽  
pp. 1295-1305 ◽  
Author(s):  
Jérôme Meunier ◽  
Livia Lumbroso-Le Rouïc ◽  
Rémi Dendale ◽  
Anne Vincent-Salomon ◽  
Bernard Asselain ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Natural History ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Single Center ◽  
Non Hodgkin’S Lymphoma ◽  
Single Center Study ◽  
Non Hodgkin's Lymphoma ◽  
Center Study

Response to Re-Treatment with Rituximab Plus Salvage-Chemotherapy in Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4720-4720 ◽  
Author(s):  
Andrea Borgerding ◽  
Justin Hasenkamp ◽  
Bjoern Chapuy ◽  
Lorenz Truemper ◽  
Gerald Wulf ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Progressive Disease ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Autologous Graft ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract The efficacy of re-therapy with rituximab immuno-chemotherapy was analysed in 20 consecutive patients with relapsed or progressive aggressive Non Hodgkin’s lymphoma after initial treatment with rituximab plus chemotherapy. Ten patients had a diffuse large B-cell lymphoma, seven had a mantle cell lymphoma and three a grade III follicular lymphoma. At primary diagnosis, the IPI was high-intermediate or high in 75% of the patients and the median age was 55 years (range 36–72 years). The overall response rate of primary immuno-chemotherapy was 75% (15/20 patients) with a complete remission in 8/20 patients (40%). After relapse, 53 % of these patients (8/15) responded again to immunochemotherapy: two patients had a second complete and six a second partial remission. None of the five patients with primary progressive disease responded to a conventional immuno-chemo salvage therapy. After re-therapy with rituximab plus salvage chemotherapy, ten patients received at least one cycle of high dose chemotherapy followed by SCT. One patient did receive HD-chemotherapy and an autologous graft solely, two patients did receive HD-radio-immunotherapy followed by an autologous graft and seven patients finally received HDT and an allogeneic transplant. Allogeneic SCT resulted in a CR in 6 out of 7 patients. One of these ten patients relapsed after HDT consolidation. Six out of ten patients without HDT consolidation after immuno-chemotherapy progressed after secondary treatment, 4 patients are alive without progression (SD, PR) but follow up is short (7, 10, 13 and 16 months). Conclusion: A substantial proportion (53%) of patients with relapse after rituximab immuno-chemotherapy did response to rituximab containing salvage therapy. Patients with progressive disease under immuno-chemotherapy did not respond to such salvage therapy. Without additional consolidation by HDT the risk of progression after successful salvage with rituximab and salvage-chemotherapy is high.

Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma

1991 ◽  
Vol 5 (2-3) ◽  
pp. 111-115 ◽  
Author(s):  
A. Keith Stewart ◽  
Joseph M. Brandwein ◽  
Simon B. Sutcliffe ◽  
J. Gerald Scott ◽  
Armand Keating
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone

1989 ◽  
Vol 25 (2) ◽  
pp. 135-138 ◽  
Author(s):  
Takashi Yoshida ◽  
Shinobu Nakamura ◽  
Shigeki Ohtake ◽  
Kazumi Kobayashi ◽  
Masatoshi Kanno ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

Cancer ◽  
1996 ◽  
Vol 77 (11) ◽  
pp. 2302-2307 ◽  
Author(s):  
Aspasia Stamatoullas ◽  
Christophe Fruchart ◽  
Dominique Bastit ◽  
Dominique Boulet ◽  
Mathieu Monconduit ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document